OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.
For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk. By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...
An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new recommendations for good clinical practice—a set of guidelines that helps ensure clinical trial results are reliable, and patients are protected—regarding the use of artificial intelligence methods to more accurately diagnose, monitor, and treat brain cancer patients. The team recently published two companion...
